Randomized phase II non-inferiority study (no16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 589-597

  Buzdar, A U ^a   Xu, B ^b   Digumarti, R ^c   Goedhals, L ^d   Hu, X ^e   Semiglazov, V ^f   Cheporov, S ^g   Gotovkin, E ^h   Hoersch, S ^h   Rittweger, K ⁱ   Miles, D W ^j   O'shaughnessy, J ^k   Tjulandin, S ^l  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CANCER HOSPITAL   (China)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^d National Hospital Bloemfontein   (South Africa)

^e FUDAN UNIVERSITY   (China)

^f N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^g Department of Oncology   (Russian Federation)

^h Regional Oncology Dispensary ^*  (Germany)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j MOUNT VERNON HOSPITAL   (United Kingdom)

^k TEXAS ONCOLOGY   (United States)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

more..

Author keywords

Capecitabine; Docetaxel; Dose modification; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

EID: 84863255333     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr256     Document Type: Article

References (21)

1. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
2. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83: 127-134.
3. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18: 343-354.
4. Sawada N, Fujimoto-Ouchi K, Ishikawa T et al. Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002; 43: 1088 (Abstr 5388).
5. Stockler M, Sourjina T, Grimison P et al. A randomized trial of capecitabine given intermittently rather than continuously compared to classical CMF as first-line chemotherapy for advanced breast cancer. J Clin Oncol Suppl 2007; 18 (Abstr 1031).
6. Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; 21: 2145-2152.
7. Kaufmann M, Maass N, Costa SD et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur J Cancer 2010; 7: 46: 3184-3191.
8. Nabholtz J-M, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-1424.
9. Sjöström J, Blomqvist C, Mourisden H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-1200.
10. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
11. Miles D, Vukelja S, Moiseyenko V et al. Survival benefit with capecitabine/ docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004; 5: 273-278.
12. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379-1385.
13. Blum JL, Jones SE, Buzdar AU et al. Capecitabine in 162 patients with paclitaxelpretreated MBC: updated results and analysis of dose modification. Eur J Cancer Suppl 2001; 37 (Abstr 693).
14. Hennessy BT, Gauthier AM, Michaud LB et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289-1296.
15. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
16. Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
17. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
18. Mavroudis D, Papakotoulas P, Ardavanis A et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010; 21: 48-54.
19. Seidman AD, Brufsky A, Ansari RH et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 2011; 22: 1094-1101.
20. Bachelot T, Bajard A, Ray-Coquard I et al. Superiority of docetaxel + capecitabine compared to docetaxel + epirubicin as first-line therapy for metastatic breast cancer-final results of the ERASME-4 study. Cancer Res Suppl 2009; 24 (Abstr 2099).
21. Michalaki V, Gennatas S, Gennatas K. Low-dose Xeloda plus docetaxel as firstline therapy for metastatic breast cancer: phase II results. Anticancer Drugs 2009; 20: 204-207.